跳至主要内容
临床试验/NCT03343314
NCT03343314已完成不适用

Effective Management of Calcific Aortic Stenosis in the Elderly

French Cardiology Society0 个研究点目标入组 1,101 人开始时间: 2016年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,101
主要终点
Collate the therapeutic decision (medical treatment, TAVI [Transcatheter Aortic Valve Implantation] or surgical aortic valve replacement) comprehensively for all hospitalized patients because of a severe, symptomatic RAC.

研究概览

简要总结

Although aortic valve replacement is recommended for any symptomatic severe calcific aortic stenosis, the therapeutic decision may be difficult. because of patient age and comorbidities.

Transcatheter Aortic Valve Implantation (TAVI) has recently extended the therapeutic indications in patients at high risk of surgery. However, the proportion of different treatments is not known in a contemporary population that can be treated according to the different resources currently available.

The scientific goal of this observational research is to evaluate intra-hospital therapeutic decision in elderly patients referred because of symptomatic severe aortic stenosis.

The one-year survival will be analyzed according to the therapeutic decision and the characteristics of the patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
75 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Hospitalized due to symptomatic tight aortic stenosis (NYHA >= II, dyspnea, angina or syncope);
  • Having given his consent to participate in the study.

排除标准

  • Non-severe aortic stenosis;
  • Asymptomatic aortic stenosis;
  • Patient under the age of 75;
  • Patient refusing to participate in the study.

结局指标

主要结局

Collate the therapeutic decision (medical treatment, TAVI [Transcatheter Aortic Valve Implantation] or surgical aortic valve replacement) comprehensively for all hospitalized patients because of a severe, symptomatic RAC.

时间窗: 1 day

The primary endpoint is the therapeutic indication retained by the medical-surgical team in charge of the patient during hospitalization: medical treatment, TAVI or surgical aortic valve replacement.

次要结局

  • 1 year-survival(1 year)

研究者

发起方
French Cardiology Society
申办方类型
Other
责任方
Sponsor

相似试验